Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $55.92 in the last session, down -0.94% from day before closing price of $56.45. In other words, the price has decreased by -$0.94 from its previous closing price. On the day, 1.05 million shares were traded. HALO stock price reached its highest trading level at $56.659 during the session, while it also had its lowest trading level at $55.64.
Ratios:
We take a closer look at HALO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.90. For the most recent quarter (mrq), Quick Ratio is recorded 7.30 and its Current Ratio is at 8.39. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 3.13.
On May 14, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $62.
Leerink Partners Downgraded its Market Perform to Underperform on May 13, 2025, while the target price for the stock was maintained at $47.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 10 ’25 when Torley Helen sold 20,000 shares for $57.43 per share. The transaction valued at 1,148,618 led to the insider holds 733,719 shares of the business.
Torley Helen sold 20,000 shares of HALO for $1,128,655 on Jul 09 ’25. The PRESIDENT AND CEO now owns 733,719 shares after completing the transaction at $56.43 per share. On Jul 08 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $55.51 each. As a result, the insider received 1,110,245 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 6890518016 and an Enterprise Value of 7198870528. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.84, and their Forward P/E ratio for the next fiscal year is 7.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.35 while its Price-to-Book (P/B) ratio in mrq is 14.28. Its current Enterprise Value per Revenue stands at 6.639 whereas that against EBITDA is 10.693.
Stock Price History:
The Beta on a monthly basis for HALO is 1.17, which has changed by 0.038829565 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $70.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 1.96%, while the 200-Day Moving Average is calculated to be 0.94%.
Shares Statistics:
According to the various share statistics, HALO traded on average about 2.57M shares per day over the past 3-months and 1419690 shares per day over the past 10 days. A total of 123.17M shares are outstanding, with a floating share count of 121.86M. Insiders hold about 1.10% of the company’s shares, while institutions hold 99.31% stake in the company. Shares short for HALO as of 1749772800 were 11065499 with a Short Ratio of 3.95, compared to 1747267200 on 10690600. Therefore, it implies a Short% of Shares Outstanding of 11065499 and a Short% of Float of 12.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
